C&G Editor in Chief, Erin Harris
-
Highlights from In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
10/27/2023
Umoja Biopharma’s Dr. Andrew Scharenberg joined me as my guest on a recent episode of Cell & Gene: The Podcast to discuss the evolution of in vivo CAR-T cell therapeutics. Here are highlights from our conversation.
-
ARM’s 2023 Meeting On The Mesa: Data, Ethics, And More
10/19/2023
ARM's 2023 Meeting on the Mesa was chock full of informative sessions, impactful conversations, partnering opportunities, and peer networking. Here's a brief recap.
-
September's Top Content On Cell & Gene
9/29/2023
Here is a glimpse of the impactful content, in various formats, Cell & Gene delivered this month.
-
Dr. Jim Wilson At LSPA’s Life Sciences Future Conference
9/28/2023
LSPA's Life Science Future event included a plenary session featuring Jim Wilson Ph.D., M.D., Director, Gene Therapy Program Professor of Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania. Here's a recap of that session.
-
CBER’s Dr. Peter Marks, ARM’s Mike Lehmicke On Genome Editing Technologies
9/19/2023
Recent conversations with some of the industry's top experts show genome editing technologies are here to stay and evolving rapidly.
-
Regulating the CGT Workflow To Improve Patient Safety
8/31/2023
In case you missed it, our most recent Cell & Gene Live, Regulating the CGT Workflow To Improve Patient Safety, featuring expert panelists Nimi Chhina, Ph.D., J.D. Executive Director, Head of Global R&D and Regulatory Policy Global Regulatory Affairs, Worldwide Research & Development at BioMarin Pharmaceutical, and Bob Pietrusko, Pharm.D., Chief Regulatory & Quality Officer at Vor Biopharma, is available on demand in its entirety.
-
Bayer, BlueRock’s Parkinson’s Trial On Course For Phase 2
8/29/2023
Bayer, BlueRock's stem cell therapy for Parkinson's Disease preps for Phase 2.
-
Akamis Bio Takes On Advanced Solid Tumors
8/23/2023
Akamis Bio’s CEO, Dr. Howard Davis, explains the company's T-SIGn platform, the NG-350A trial, and how T-SIGn may impact CAR-T for solid tumors.
-
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes
8/7/2023
Efficiencies in donor selection reduce uncertainties about human leukocyte antigen (HLA) and improve patient outcomes.
-
Automation’s Role In Cell Therapy Manufacturing
7/31/2023
The need for standardization and automation are critical drivers of innovation in cell therapy manufacturing. Implementation of an automated workflow minimizes open processes and manual touchpoints, increases reproducibility, and improves traceability. This has the potential to reduce manufacturing failures and lower the cost of goods sold, thereby facilitating increased patient access.